Shanghai Pharmaceuticals Holding Co Ltd 2017 SR
The report highlights Shanghai Pharmaceuticals' 2017 performance, achieving a revenue of RMB 130.847 billion and ranking 56th on the Fortune China 500. Key achievements include obtaining 114 GMP certificates and advancing R&D with 97 projects for generic drug consistency evaluation. The company expanded its distribution network to 24 provinces and acquired Cardinal Health China to enhance its modern health services. Sustainability efforts focused on 'Healthy China' initiatives, such as the 'Shanghai Medical Care Guardian Plan' for rural healthcare and significant investments in environmental protection, including VOC remediation and water-saving technical renovations.
Company: Shanghai Pharmaceuticals Holding Co Ltd
Sector: Manufacturing
Country: China
Year: 2017
Type: SR
Pages: 120
Back to company
Shanghai Pharmaceuticals Holding Co Ltd
Environment, Society And Governance Report
The report highlights Shanghai Pharmaceuticals' 2017 performance, achieving a revenue of RMB 130.847 billion and ranking 56th on the Fortune China 500. Key achievements include obtaining 114 GMP certificates and advancing R&D with 97 projects for generic drug consistency evaluation. The company expanded its distribution network to 24 provinces and acquired Cardinal Health China to enhance its modern health services. Sustainability efforts focused on 'Healthy China' initiatives, such as the 'Shanghai Medical Care Guardian Plan' for rural healthcare and significant investments in environmental protection, including VOC remediation and water-saving technical renovations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Employees